Insider Trades
News
newsfilecorp.comKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Modelnewsfilecorp.comJun 18
businesswire.comKKR Income Opportunities Fund Declares Monthly Distributions of $0.1215 Per Sharebusinesswire.comJun 8
seekingalpha.comKIO: High Beta Fixed Income CEF With Significant Downside (Rating Downgrade)seekingalpha.comApr 17
defenseworld.netKKR Income Opportunities Fund (NYSE:KIO) Stock Crosses Above 50-Day Moving Average – Here’s What Happeneddefenseworld.netApr 17
newsfilecorp.comKiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underwaynewsfilecorp.comApr 14